Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation
Frank J. Accurso(University of Colorado Anschutz Medical Campus), Bonnie W. Ramsey(Seattle Children's Hospital), Peter R. Durie(University of Toronto), Scott H. Donaldson(University of North Carolina at Chapel Hill), Michael W. Konstan(Case Western Reserve University), Melissa A. Ashlock(Cystic Fibrosis Foundation), Ahmet Uluer(Boston Children's Museum), Richard B. Moss(Palo Alto University), Steven D. Freedman(Beth Israel Deaconess Medical Center), Jiuhong Zha(AbbVie (United States)), Preston W. Campbell(Cystic Fibrosis Foundation), Jordan Dunitz(University of Minnesota System), Lynn M. Rose(Seattle Children's Hospital), Douglas B. Hornick(University of Iowa), Nicole Mayer-Hamblett(Seattle Children's Hospital), Scott D. Sagel(SUNY Upstate Medical University), Ronald C. Rubenstein(West Chester University), Anne J. Stone(Vertex Pharmaceuticals (United States)), Moira L. Aitken(University of Washington), Michael Boyle(McMaster University), John P. Clancy(Cystic Fibrosis Foundation), Claudia L. Ordoñez(Vertex Pharmaceuticals (United States)), Eric R. Olson(Vertex Pharmaceuticals (United States)), Steven M. Rowe(University of Alabama at Birmingham), Qunming Dong(Vertex Pharmaceuticals (United States)), Joseph M. Pilewski(University of Pittsburgh)
Cited by 802
Related Papers
Update on Key Emerging Challenges in Cystic Fibrosis
|Medical Principles and Practice|2014|3.7k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Multiattribute and Single-Attribute Utility Functions for the Health Utilities Index Mark 3 System
|Medical Care|2002|1.3k
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
|New England Journal of Medicine|1999|1.3k